The Commission is mobilising €123 million from Horizon Europe, the new EU research and innovation programme, for urgent research into coronavirus variants. This first emergency funding under Horizon Europe contributes to the Commission’s overall action to prevent, mitigate and respond to the impact of coronavirus variants, in line with the new European bio-defence preparedness plan HERA Incubator.
They will support the development of large scale, COVID-19 cohorts and networks beyond Europe’s borders, forging links with European initiatives, as well as reinforce the infrastructures needed to share data, expertise, research resources and expert services among researchers and research organisations.
The projects funded are expected to:
- Establish new and/or build on existing large-scale, multi-centre and regional or multinational cohorts, including beyond Europe’s borders, which should rapidly advance the knowledge on SARS-CoV-2 and its emerging variants.
- Further develop promising therapeutic or vaccine candidates against SARS-CoV-2/COVID-19, having already completed preclinical development in clinical studies.
- Support research infrastructures to speed up data sharing and deliver fast research support and expertise, to confront the coronavirus variants and to be ready for future epidemics.
The successful consortia are expected to collaborate with other relevant initiatives and projects at national, regional, and international level to maximise synergies and complementarity and avoid duplication of the research efforts.
These emergency calls will tackle the short to medium-term threat and simultaneously prepare for the future. They will contribute to building the European Health Emergency Preparedness and Response Authority (HERA), which will enable the EU to anticipate and better tackle future pandemics.
The calls will open for submissions on 13 April and the deadline for submission is 6 May 2021. The new solutions need to be available and affordable for all, in line with the principles of the Coronavirus Global Response.